<DOC>
	<DOCNO>NCT00595959</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy CLiRpath® Photoablation Atherectomy System consist Bias Sheath guide catheter , combination available CLiRpath® Excimer Laser Catheters ≤ 2.0 mm , create large lumens treatment within superficial femoral popliteal artery knee .</brief_summary>
	<brief_title>CELLO - CLiRpath® Excimer Laser System Enlarge Lumen Openings</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>General Inclusion Criteria 1 . Peripheral vascular disease Rutherford Classification 1 , 2 , 3 ; 2 . Eligible revascularization native vessel ( PTA bypass ) ; 3 . Willing able comply specify evaluation hospitalization require followup examination ; 4 . Written informed consent give execution study procedure ; 5 . Age &gt; 18 ≤ 85 year . Angiographic Inclusion Criteria 1 . Reference vessel diameter &gt; /= 4.0 mm ≤ 7.0 mm determine physician visual angiographic assessment normally appear vessel segment within 10 mm proximal AND 10 mm distal target segment . 2 . Stenosis within SFA and/or popliteal artery knee &gt; /= 70 % &lt; /= 100 % DS ( occlusion ) , determine visual angiographic assessment investigator time procedure document angiography least two ( 2 ) orthogonal view . 3 . At least 1.0 cm visible SFA stump beyond origin profunda artery . 4 . Total lesion length &gt; /= 1.0 cm ≤ 15.0 cm determine visual angiographic assessment time procedure , separate multiple lesion combine two separate treatment area long sum total lesion length and/or treatment area exceed 1.0 cm 15.0 cm . 5 . Patency ( &lt; 50 % DS ) least one ( 1 ) infrapopliteal artery continuity native femoropopliteal artery . General Exclusion Criteria 1 . Contraindication intravenous contrast material , heparin , aspirin medication require percutaneous interventional procedure ; 2 . Known bleed hypercoagulation disorder ; 3 . Serum creatinine &gt; 2.0 mg/dL ; 4 . Uncompensated congestive heart failure ; 5 . Current enrollment investigational study wherein patient participation complete ; 6 . Prior enrollment study ; 7 . Suspected confirmed pregnancy ; 8 . Any patient , opinion investigator , would good candidate enrollment ; 9 . Myocardial infarction within 60 day ; 10 . CVA/TIA within 60 day . Angiographic Exclusion Criteria 1 . 1 . Subintimal guidewire placement follow pilot channel creation stenosis occlusion excimer laser catheter , visualized IVUS ; 2 . Calcification likely prevent passage excimer laser catheter CLiRpath® Photoablation Atherectomy system ; 3 . Ipsilateral and/or contralateral iliac stenosis &gt; /= 50 % DS treat prior enrollment study ; 4 . Ipsilateral and/or contralateral iliac treatment stenosis prior enrollment final residual stenosis &gt; /= 30 % , determine least two ( 2 ) orthogonal view document angiography ; 5 . Iliac treatment prior enrollment perforation occur require cover stent , blood transfusion , surgery treatment perforation ; 6 . Identification lesion knee and/or knee treat leg ( ipsilateral ) require preplanned predicted treatment within six ( 6 ) month enrollment prior completion six ( 6 ) month followup , include iliac artery , common femoral artery , peroneal , anterior tibial , posterior tibial artery , area iliacs foot outside treatment area ; 7 . Lesions proximal distal treatment site &gt; /= 50 % DS time enrollment ; 8 . Contralateral leg disease require treatment within next 30 day prior completion 30 day followup ; 9 . Cardiovascular surgical cardiovascular interventional procedure ( include , limited , aortic , renal , cardiac , carotid , femoropopliteal , knee ) within 30 day prior enrollment study ; 10 . Planned predict cardiovascular surgical interventional procedure outside ipsilateral leg ( include , limited aortic , renal , cardiac , carotid , contralateral femoropopliteal , contralateral knee ) within 30 day entry study , prior completion 30day followup ; 11 . Perforation dissection grade `` C '' great see creation pilot channel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>